Crescent Biopharma, Inc. (CBIO)
14.65
-0.10
(-0.71%)
USD |
NASDAQ |
Nov 12, 16:00
14.65
0.00 (0.00%)
After-Hours: 18:22
Crescent Biopharma Enterprise Value : 243.38M for Nov. 11, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 11, 2026 | 243.38M |
| November 10, 2026 | 220.21M |
| November 09, 2026 | 212.71M |
| November 06, 2026 | 209.66M |
| November 05, 2026 | 193.01M |
| November 04, 2026 | 217.43M |
| November 03, 2026 | 196.34M |
| November 02, 2026 | 192.17M |
| October 30, 2026 | 207.99M |
| October 29, 2026 | 224.37M |
| October 28, 2026 | 208.55M |
| October 27, 2026 | 202.17M |
| October 26, 2026 | 188.01M |
| October 23, 2026 | 189.68M |
| October 22, 2026 | 198.56M |
| October 21, 2026 | 199.39M |
| October 20, 2026 | 196.61M |
| October 19, 2026 | 176.91M |
| October 16, 2026 | 162.48M |
| October 15, 2026 | 180.24M |
| October 14, 2026 | 183.01M |
| October 13, 2026 | 192.17M |
| October 12, 2026 | 235.20M |
| October 09, 2026 | 247.69M |
| October 08, 2026 | 225.76M |
| Date | Value |
|---|---|
| October 07, 2026 | 208.27M |
| October 06, 2026 | 210.49M |
| October 05, 2026 | 220.76M |
| October 02, 2026 | 231.31M |
| October 01, 2026 | 229.64M |
| September 30, 2026 | 238.80M |
| September 29, 2026 | 243.52M |
| September 28, 2026 | 237.14M |
| September 25, 2026 | 222.15M |
| September 24, 2026 | 229.09M |
| September 23, 2026 | 227.70M |
| September 22, 2026 | 290.15M |
| September 21, 2026 | 284.88M |
| September 18, 2026 | 302.64M |
| September 17, 2026 | 299.31M |
| September 16, 2026 | 310.69M |
| September 15, 2026 | 355.66M |
| September 14, 2026 | 380.08M |
| September 11, 2026 | 372.59M |
| September 10, 2026 | 373.98M |
| September 09, 2026 | 388.69M |
| September 08, 2026 | 401.73M |
| September 04, 2026 | 413.39M |
| September 03, 2026 | 400.07M |
| September 02, 2026 | 348.44M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Encompass Health Corp. | 17.52B |
| Myriad Genetics, Inc. | 649.70M |
| BioRestorative Therapies, Inc. | -1.570M |
| U.S. Stem Cell, Inc. | -- |
| Marijuana, Inc. | -14.13M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -24.84M |
| Total Expenses (Quarterly) | 24.84M |
| EPS Diluted (Quarterly) | -0.8135 |
| Earnings Yield | -52.20% |
| Normalized Earnings Yield | -52.20 |